VEGI downregulation is correlated with nodal metastasis and poor prognosis in lung adenocarcinoma

Xu,Yinhai; Liu,Zhao; Li,Ham; Feng,Shoujie; Li,Qingpeng; Li,Junfeng; Li,Shibao

doi:10.3892/mco.2020.2187

VEGI downregulation is correlated with nodal metastasis and poor prognosis in lung adenocarcinoma

Authors:
- Yinhai Xu
- Zhao Liu
- Ham Li
- Shoujie Feng
- Qingpeng Li
- Junfeng Li
- Shibao Li
View Affiliations

Affiliations: Department of Laboratory Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, Department of Thyroid and Breast Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, School of Foreign Studies, Jiangsu Normal University, Xuzhou, Jiangsu 221116, P.R. China, Department of Thoracic Cardiovascular Surgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China, Department of Endocrinology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: December 9, 2020 https://doi.org/10.3892/mco.2020.2187
Article Number: 25
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the incidence of lung cancer is increasing worldwide, the molecular mechanisms for its tumorigenesis, progression and prognosis remain unknown. As a member of the tumor necrosis factor superfamily, vascular endothelial growth inhibitor (VEGI) is involved in the development and progression of many malignant diseases. In the present study, the expression of VEGI and CD31 was examined via immunohistochemistry in non‑small cell lung cancer (NSCLC) tissues obtained from 150 patients with NSCLC. The inhibitory effect of VEGI on tumor‑associated blood vessel formation and growth was investigated by determining the relationship between VEGI protein expression and microvascular density (MVD). Prognostic significance was evaluated using the Kaplan‑Meier method. VEGI expression was downregulated or lost in 68.7% (103/150) of patients with NSCLC, an effect that was more prevalent in adenocarcinoma (AC), 76.0% (57/75), than in squamous cell carcinoma, 61.3% (46/75). A significant negative correlation was indentified between VEGI expression and lymphovascular invasion (P=0.039) and lymph node metastasis (P=0.017) in AC tissue. Additionally, MVD was significantly lower in the VEGI‑rich group compared with the VEGI‑poor group. The downregulation of VEGI expression was also associated with poorer overall survival (P=0.011) in patients with AC. The present study therefore provides evidence that VEGI may be a new and effective prognostic marker of lung AC.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
2	Zhang S, Fu Y, Wang D and Wang J: Icotinib enhances lung cancer cell radiosensitivity in vitro and in vivo by inhibiting MAPK/ERK and AKT activation. Clin Exp Pharmacol Physiol. 45:969–977. 2018.PubMed/NCBI View Article : Google Scholar
3	Sen Z, Zhan XK, Jing J, Yi Z and Wanqi Z: Chemosensitizing activities of cyclotides from Clitoria ternatea in paclitaxel-resistant lung cancer cells. Oncol Lett. 5:641–644. 2013.PubMed/NCBI View Article : Google Scholar
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
5	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
6	Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E and Bray F: International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 84:13–22. 2014.PubMed/NCBI View Article : Google Scholar
7	Vansteenkiste J, Crinò L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, et al: 2nd ESMO Consensus Conference on Lung Cancer: Early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 25:1462–1474. 2014.PubMed/NCBI View Article : Google Scholar
8	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.PubMed/NCBI View Article : Google Scholar
9	Parr C, Gan CH, Watkins G and Jiang WG: Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis. 9:73–81. 2006.PubMed/NCBI View Article : Google Scholar
10	Zhang N, Sanders AJ, Ye L and Jiang WG: Vascular endothelial growth inhibitor in human cancer (Review). Int J Mol Med. 24:3–8. 2009.PubMed/NCBI View Article : Google Scholar
11	Zhang N, Sanders AJ, Ye L, Kynaston HG and Jiang WG: Vascular endothelial growth inhibitor, expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro. Int J Oncol. 35:1473–1480. 2009.PubMed/NCBI View Article : Google Scholar
12	Zhang N, Sanders AJ, Ye L, Kynaston HG and Jiang WG: Expression of vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its effects on the adhesion and migration of bladder cancer cells in vitro. Anticancer Res. 30:87–95. 2010.PubMed/NCBI
13	Wu L, Li X, Ye L, Shayiremu D, Deng X, Zhang X, Jiang W, Yang Y, Gong K and Zhang N: Vascular endothelial growth inhibitor 174 is a negative regulator of aggressiveness and microvascular density in human clear cell renal cell carcinoma. Anticancer Res. 34:715–22. 2014.PubMed/NCBI
14	Zhao Q, Liu T, Hong B, Wang F, Zhou C, Du X, Chen S, Deng X, Duoerkun S, Li Q, et al: Vascular endothelial growth inhibitor, a cytokine of the tumor necrosis factor family, is associated with epithelial-mesenchymal transition in renal cell carcinoma. Appl Immunohistochem Mol Morphol. 26:727–733. 2018.PubMed/NCBI View Article : Google Scholar
15	Hou W, Medynski D, Wu S, Lin X and Li LY: A new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res. 11:5595–5602. 2005.PubMed/NCBI View Article : Google Scholar
16	Liang PH, Tian F, Lu Y, Duan B, Stolz DB and Li LY: Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors. Angiogenesis. 14:61–68. 2011.PubMed/NCBI View Article : Google Scholar
17	Chen Y, Mathy NW and Lu H: The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). Mol Med Rep. 17:8019–8030. 2018.PubMed/NCBI View Article : Google Scholar
18	Karoor V, Le M, Merrick D, Fagan KA, Dempsey EC and Miller YE: Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism. Cancer Prev Res (Phila). 5:1061–1071. 2012.PubMed/NCBI View Article : Google Scholar
19	Yu X, Li W, Deng Q, You S, Liu H, Peng S, Liu X, Lu J, Luo X, Yang L, et al: Neoalbaconol Inhibits angiogenesis and Tumor Growth by suppressing EGFR-mediated VEGF production. Mol Carcinog. 56:1414–1426. 2017.PubMed/NCBI View Article : Google Scholar
20	Zhang K, Cai HX, Gao S, Yang GL, Deng HT, Xu GC, Han J, Zhang QZ and Li LY: TNFSF15 suppresses VEGF production in endothelial cells by stimulating miR-29b expression via activation of JNK-GATA3 signals. Oncotarget. 7:69436–69449. 2016.PubMed/NCBI View Article : Google Scholar
21	Gao Y, Ge Z, Zhang Z, Bai Z, Ma X and Wang Y: Vascular endothelial growth inhibitor affects the invasion, apoptosis and vascularisation in breast cancer cell line MDA-MB-231. Chin Med J (Engl). 127:1947–1953. 2014.PubMed/NCBI
22	Jia W, Sander AJ, Jia G, Ni M, Liu X, Lu R and Jiang WG: Vascular endothelial growth inhibitor (VEGI) is an independent indicator for invasion in human pituitary adenomas. Anticancer Res. 33:3815–3822. 2013.PubMed/NCBI
23	Duan L, Yang G, Zhang R, Feng L and Xu C: Advancement in the research on vascular endothelial growth inhibitor (VEGI). Target Oncol. 7:87–90. 2012.PubMed/NCBI View Article : Google Scholar